Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

Inclusion Criteria

• Patients with biopsy proven localized prostate cancer in whom prostate radiation and ADT is appropriate therapy (such as Intermediate Risk localized prostate cancer)
• Patients must have at least 1 MRI detected; biopsy proven prostate cancer.
• Patients diagnosed as one of the following:
• National Comprehensive Cancer Network (NCCN) intermediate risk prostate cancer, OR
• NCCN high risk prostate cancer due to Gleason Grade 4 or 5 AND refuses to receive systemic ADT, OR
• NCCN high risk prostate cancer due to Prostate Specific Antigen (PSA) > 20 AND refuses to receive systemic ADT.
• Age >18 years.

Exclusion Criteria

• NCCN high risk patients eligible for treatment with systemic ADT who do not refuse systemic ADT.
• Patients receiving prior radiotherapy or surgery for prostate cancer.
• Patients receiving prior or ongoing ADT.
• Study participant unwilling or unable to undergo MRI, including patients with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.
• Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of > 3 months.
• Prostate volume more than 80 cc at prior MRI imaging.
• International Prostate Symptom Score ≥ 20.